The SK2 subtype of small conductance Ca 2؉ -activated K ؉ channels is widely distributed throughout the central nervous system and modulates neuronal excitability by contributing to the afterhyperpolarization that follows an action potential. Western blots of brain membrane proteins prepared from wild type and SK2-null mice reveal two isoforms of SK2, a 49-kDa band corresponding to the previously reported SK2 protein (SK2-S) and a novel 78-kDa form. Complementary DNA clones from brain and Western blots probed with an antibody specific for the longer form, SK2-L, identified the larger molecular weight isoform as an N-terminally extended SK2 protein. The N-terminal extension of SK2-L is cysteine-rich and mediates disulfide bond formation between SK2-L subunits or with heterologous proteins. Immunohistochemistry revealed that in brain SK2-L and SK2-S are expressed in similar but not identical patterns. Heterologous expression of SK2-L results in functional homomeric channels with Ca 2؉ sensitivity similar to that of SK2-S, consistent with their shared core and intracellular C-terminal domains. In contrast to the diffuse, uniform surface distribution of SK2-S, SK2-L channels cluster into sharply defined, distinct puncta suggesting that the extended cysteine-rich Nterminal domain mediates this process. Immunoprecipitations from transfected cells and mouse brain demonstrate that SK2-L co-assembles with the other SK subunits. Taken together, the results show that the SK2 gene encodes two subunit proteins and suggest that native SK2-L subunits may preferentially partition into heteromeric channel complexes with other SK subunits.
SK channels are voltage-independent K ϩ channels that are activated by elevated levels of intracellular Ca 2ϩ , such as occur following an action potential (1) . In many central neurons, SK channel activity dampens excitability by contributing to the afterhyperpolarization, affecting interspike intervals during a burst of action potentials as well as the length of the burst (2) (3) (4) (5) .
SK1, SK2, and SK3 are expressed in overlapping yet distinct patterns throughout the central nervous system with SK2 being the most highly expressed (6 -8) . These genes are also expressed in many peripheral tissues along with the fourth member of the SK gene family, IK1 (SK4), whose expression is limited to the periphery (9) . 1 Apamin specifically blocks SK1-3 channels, and the physiological consequences of apamin application likely reflect SK channel blockade. Apamin block of hippocampal SK channels facilitates the induction of synaptic plasticity at CA3 Schaffer collateral to CA1 synapses. Consistent with this result, systemic apamin injection facilitates the acquisition of hippocampal dependent learning (10) . These effects depend upon SK2 channels as SK2-null mice lack apaminsensitive currents in CA1 neurons, but these currents are unchanged in SK1-null or SK3-null mice (11) .
SK channels share the six transmembrane domain topology of the Shaker prototype. Within their transmembrane core domains the different SK subunits are highly homologous but exhibit considerable divergence in their intracellular N-and extreme C-terminal domains. The most highly conserved domain is the calmodulin-binding domain in the proximal C terminus. Calmodulin is constitutively associated with the channel and gating is a result of Ca 2ϩ binding to the N-lobe E-F hands of CaM 2 (12) . Protein kinase CK2 also associates with SK channels, forming a multimeric complex that may include additional components. In this complex, CK2 phosphorylates CaM and modulates the Ca 2ϩ sensitivity of the channels (13) . Heterologous expression studies showed that rat or mouse SK2 and SK3, but not SK1 subunits, form functional homomeric channels, and all three subtypes are capable of co-assembly (14 -16) . In contrast, other reports suggest that SK channels form exclusively homomeric channels in the brain, indicating that there may be mechanisms to compartmentalize the different SK subtypes and prevent heteromeric channel formation (17) .
To investigate the macromolecular composition of SK2-containing complexes in vivo, membrane protein extracts from wild type and SK2-null mice were examined, revealing a previously unknown N-terminally extended SK2 subunit. This novel SK isoform, SK2-L, is expressed in a subset of SK2-expressing neurons, and both forms of SK2 co-assemble into heteromeric channels with the other SK subunits.
MATERIALS AND METHODS
Molecular Biology-An SK2 cDNA sequence (GenBank TM accession number AK033158) from mouse testis was used to design a primer for amplification of SK2-L from mouse brain cDNA. The entire SK2-L coding sequence was amplified with Pfu Turbo (Stratagene, La Jolla, * The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
ʈ To whom correspondence should be addressed: Oregon Health & Science University, 3181 SW Sam Jackson Park Rd., Portland, OR 97239. Tel.: 503-494-5450; Fax: 503-494-4353; E-mail: adelman@ ohsu.edu. CA) using the 5Ј-primer TCGGGAGAACGTGCAAATGTGA and the 3Ј-primer CTAGCTACTCTCTGATGAAGTTG. Sequencing of two independent clones revealed three discrepancies with the mouse testis cDNA sequence, deletion of C712, A968C, and A1066C (numbering according to GenBank TM accession number AK033158). Deletion of C712 results in a frameshift that extends the predicted open reading frame at the N terminus. For expression in transient transfections, the SK2-L coding sequence was cloned into the cytomegalovirus-based vector, pJPA. Site-directed mutagenesis was performed using Pfu DNA polymerase (Stratagene, La Jolla, CA). The tandem triple myc epitope (EQKLISEEDL) was inserted at the S3-S4 loop of SK2-L or SK2-S using complementary oligonucleotides cloned into a BamHI site that had been introduced by site-directed mutagenesis (18) . Similarly, the C8 epitope (PRGPDRPEGIEE) was appended to the N terminus of the channels. All sequences were verified by DNA sequence analysis.
Antibodies-A rabbit polyclonal antibody raised against a peptide from the C terminus of SK2 (␣-SK2-C) has been described previously (11) . A polyclonal antibody (␣-SK2-L) was raised in rabbits against a peptide from the N terminus of SK2-L (METPLQFQRGFFPEQP). A cysteine residue was included at the C terminus to allow coupling to cysteine-reactive Sepharose (Sulfo-Link, Pierce). Both ␣-SK2 polyclonal antibodies were purified by peptide affinity chromatography. Mouse monoclonal ␣-C8 antibody was purified from the tissue culture supernatant of Chessie 8 (C8) hybridoma (19) . Mouse monoclonal ␣-CaM antibody was purchased from Upstate Biotechnology (Charlottesville, VA). Mouse monoclonal ␣-myc antibody was from Invitrogen. A rabbit polyclonal ␣-SK2 antibody was purchased from Alomone Laboratories. Purified ␣-SK2-L antibody was coupled to CNBr-activated Sepharose (Sigma) according to the manufacturer's instructions at 2 mg of antibody/ml of Sepharose.
Mouse Brain Membrane Preparations-Whole mouse brains were homogenized in ice-cold HS (in mM: 320 sucrose, 10 Hepes, 1 EGTA) supplemented with Sigma mammalian protease inhibitor mixture in a glass/ Teflon homogenizer. An initial centrifugation (10 min at 900 ϫ g) removed unbroken cells and nuclei; the resulting supernatant was centrifuged for 15 min at 10,000 ϫ g. The supernatant (light membrane fraction), was centrifuged at 150,000 ϫ g for 30 min to collect the membranes. The 10,000 ϫ g pellet was processed further by fractionation on a sucrose step gradient. First, the membranes were resuspended in hypotonic HE (10 mM Hepes, 1 mM EGTA, pH 7.4) and incubated on ice for 30 min. Following this hypotonic lysis, the membranes were collected by centrifugation at 27,000 ϫ g for 30 min. The pellet was resuspended in buffer HS and layered on a sucrose step gradient (0.32, 0.8, 1.0, and 1.2 M sucrose in buffer HE) and centrifuged at 150,000 ϫ g for 90 min in a Beckman Sw41Ti rotor. Membranes were collected from the 1.0/1.2 M sucrose interface, diluted with HE, and pelleted by centrifugation at 150,000 ϫ g for 30 min. All membranes were resuspended in HS, and protein content was determined using the BCA method (Pierce) and verified by SDS-PAGE and Coomassie staining.
Western Blots-Thirty-g samples of light membrane or sucrose gradient purified brain membranes were mixed in SDS-PAGE loading buffer supplemented with 50 mM dithiothreitol for reducing conditions or 12.5 mM N-ethylmaleimide for non-reducing conditions prior to SDS-PAGE separation. N-Ethylmaleimide was included to prevent formation of disulfide bonds upon SDS denaturation. Unless specified, reducing conditions were employed. Proteins separated by SDS-PAGE were transferred to nitrocellulose or PVDF membranes. Primary antibodies were diluted in 3% nonfat dry milk in PBS as follows: ␣-CaM to 0.5 g/ml, ␣-C8 to 0.2 g/ml, Alomone ␣-SK2 to 0.4 g/ml, ␣-SK2C to 2 g/ml for brain membranes (or 0.1 g/ml for COS membranes), and ␣-SK2-L to 5 g/ml. Horseradish peroxidase-conjugated secondary antibodies were diluted 1:10,000 in PBS containing 0.1% Tween 20. Blots were developed with SuperSignal West Pico (Pierce) according to the manufacturer's protocol.
Immunoprecipitation-Brain membranes (at 5 mg/ml) were solubilized in buffer A (in mM: 190 NaCl, 10 KCl, 10 Hepes, 1 EGTA, pH 7.4) containing 1% ␤-D-dodecyl maltoside (DDM) (Anatrace, Maumee, OH) for 45 min at 4°C. Insoluble material was removed by centrifugation at 150,000 ϫ g for 30 min at 4°C. 15 mg of solubilized membrane protein were incubated with 15 l of ␣-SK2-L-Sepharose beads overnight at 4°C. The beads were washed 15 times with 1 ml of buffer A containing 0.1% DDM. Bound proteins were eluted at room temperature with a denaturing solution (8 M urea, 0.1% DDM, and 10 mM Hepes, pH 7.4). COS cells were harvested 24 h post-transfection, and the immunoprecipitation of SK2-L was performed as described above except that buffer B (in mM: 490 NaCl, 10 KCl, 10 Hepes, 1 EGTA, pH 7.4) replaced buffer A. For each 10-cm dish of COS cells, 1 ml of buffer B containing 1% DDM was used for solubilization. Control immunoprecipitations were performed by combining 0.5 ml of SK2-L-transfected COS cells with 0.5 ml of C8-SK1-, C8-SK2-S-, or C8-SK3-transfected COS cells at the start of solubilization. In each immunoprecipitation, 10 l of ␣-SK2-L-Sepharose was used, and binding proceeded for 90 min at 4°C.
Cell Culture and Transfection-COSm6 cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and penicillin/streptomycin and CHO cells in Ham's/F-12 with the same supplements. CHO and COS cells were transfected using FuGENE 6 (Roche Applied Science) according to the manufacturer's instructions. For electrophysiological recordings and immunocytochemistry cells were co-transfected with a channel expression plasmid and a green fluorescent protein expression plasmid at a 9:1 ratio.
Electrophysiology-Recordings were performed at room temperature 1-2 days after transfection under phase contrast using an EPC9 amplifier (Instrutech Corp., Port Washington, NY) interfaced to a Macintosh G4. Data were collected using Pulse software (Heka Elektronik, Southboro, MA) and analyzed using Igor (Wavemetrics, Lake Oswego, OR). Transfected cells were identified by fluorescence. Whole-cell recordings pipettes were prepared from thin-walled borosilicate glass (World Precision Instruments, Sarasota, FL) and had resistances of 3-4 M⍀ when filled with (in mM) 150 KCl, 10 HEPES, 1 EGTA, pH-adjusted to 7.2 with NaOH, after adding CaCl 2 to 10 M. The bath solution was 30 KCl, 112 NaCl, 10 dextrose, 10 Hepes, 1 MgCl 2 , 1 CaCl 2 (pHadjusted to 7.2 with NaOH). Current amplitudes were measured at Ϫ80 mV before and after application of 100 M D-tubocurarine. For excised patch recordings macroscopic currents were measured in symmetrical K ϩ solution containing (in mM) 150 KOH, 10 HEPES, and 1 EGTA, supplemented with CaCl 2 , pH-adjusted to 7.2 with methanesulfonic acid; the amount of CaCl 2 required to yield the indicated concentrations was calculated according to Fabiato and Fabiato (20) . Current amplitudes for the Ca 2ϩ dose response were measured at Ϫ80 mV unless otherwise indicated.
Immunostaining-For transfected cells immunocytochemistry was performed 1-2 days post-transfection. Live cell immunostaining was performed by incubating the cells at 37°C with a 1:250 dilution of ␣-myc monoclonal antibody (Invitrogen) in complete medium for 10 min. After five washes in PBS ϩ (1ϫ phosphate-buffered saline containing 1 mM MgCl 2 and 1 mM CaCl 2 ), cells were fixed with 4% paraformaldehyde at room temperature for 15 min. Cells were washed three times with PBS ϩ and incubated with a Texas Red-conjugated horse anti-mouse IgG (HϩL) (Vector, Burlingame, CA) at 1:5000 in PBS ϩ supplemented with 10 mg/ml bovine serum albumin and 0.1% Triton X-100 for 30 min at room temperature. Cells were then washed three times with PBS ϩ and mounted (ProLong Antifade Kit, Molecular Probes, Eugene, OR) for imaging. Images were acquired with epifluorescence using an optical microscope Axioplan2 (Zeiss, Thornwood, NY) and OpenLab program (Improvision, Lexington, MA).
For tissue sections, immunohistochemistry with the pan-SK2 antibody, ␣-SK2-C, was performed as described previously (8), and for ␣-SK2-C and ␣-SK2-L affinity-purified antibody was used at a final concentration of 0.5 g/ml. Experiments applying the ␣-SK2-L antibody used free-floating 40-m mouse brain cryosections (perfused with 4% paraformaldehyde and 0.5% glutaraldehyde). These sections were subjected to an antigen retrieval solution from Dako (Glostrup, Denmark) for 7 min at 70°C and thereafter permeabilized for 90 min in TBS, pH 7.4, 0.4% Triton X-100 (TBS-T). Subsequently, nonspecific binding sites were blocked with 10% normal goat serum in TBS-T for 90 min and the ␣-SK2-L antibody was applied overnight (in TBS-T containing 3% normal goat serum). In control experiments, the antibody was pre-adsorbed with 20 M immunogenic peptide, or the respective pre-immune serum was used. Three rinses in TBS-T were performed before incubation with the secondary antibody (horseradish peroxidase-coupled goat anti-rabbit IgG, 1:400) for 150 min. Finally, the sections were washed with TBS, pH 8.0, and SK2-L immunoreactivity was visualized by reaction with 0.63 mM 3,3Ј-diaminobenzidine, 10 mM nickel ammonium sulfate, and 0.002% H 2 O 2 in TBS, pH 8.0. The sections were analyzed using a Zeiss Axioplan 2 microscope (Zeiss, Oberkochen, Germany) equipped with a Zeiss Axio Cam digital camera.
RESULTS
Native SK2 subunits were investigated by performing Western blots of brain membrane preparations from wild type and SK2-null mice (11), using a commercially available antibody (Alomone). While this antibody detected the 49-kDa SK2 protein from SK2-transfected COS cells, it was unable to detect SK2 in brain membrane preparations (Fig. 1) . Although three bands were detected with this antibody, the presence of all three bands in the membrane preparations from SK2-null mice indicated that they did not correspond to SK2. Therefore a new polyclonal antibody, ␣-SK2-C, was raised against a synthetic peptide epitope from the distal C-terminal domain of mSK2. With this affinity-purified antibody, a single 49-kDa protein was detected from SK2-transfected COS cells but not from cells transfected with mouse SK1 or rat SK3 (Fig. 2A) . Similarly, a 49-kDa protein was detected on Western blots of brain membrane preparations from wild type, but not SK2-null mice (Fig. 2B) . Closer inspection of the Western blots from brain revealed that in addition to the 49-kDa SK2 protein, a second larger protein of ϳ78 kDa was present in wild-type, but not SK2-null mice.
The mouse sequence database was searched to determine the identity of the larger SK2 protein, SK2-L. A single entry from embryonic mouse testis (GenBank TM accession number AK033158.1) was found that contained an extended N-terminal coding region relative to cloned SK2. If the most 5Ј-translational initiation codon is used, this domain extends the coding sequence by 275 amino acids. Expression of a longer SK2 transcript in brain was confirmed by cloning the SK2-L cDNA from mouse brain. Four in-frame methionine codons are present in this extended transcript, three in the contiguous open reading frame on exon 1, with the most 5Ј being located on upstream exon C (Fig. 2C) . It is not yet clear which of these codons serves for initiation of SK2-L translation. However, the M r of heterologously expressed SK2-L utilizing the most 3Ј start codon is most similar to the M r of SK2-L from brain.
A polyclonal antibody was generated using a peptide antigen representing an epitope in the unique N-terminal domain of SK2-L (see Fig. 2C ). On Western blots of brain membrane proteins the affinity-purified antibody recognized an ϳ80-kDa protein from wild type mice that is absent from SK2-null mice (Fig. 3A) . The apparent M r of SK2 on SDS-PAGE increases with increasing the percentage of acrylamide; the pan-SK2 antibody ␣-SK2-C also recognizes an 80-kDa band on 15% gels (data not shown).
The striking number of cysteine residues within the extended N-terminal domain of SK2-L suggests that SK2-L might form disulfide linkages either with itself or with heterologous protein partners. Indeed, SK2-L was detected in a very high molecular weight complex on SDS-PAGE under non-reducing conditions (Fig. 3B) . The migration of SK2-S, which lacks this cysteine-rich extension is unchanged in non-reducing conditions. Interestingly, the migration pattern of SK2-L expressed in COS cells was unaffected on non-reducing SDS-PAGE (data not shown).
The expression profile of SK2-S and SK2-L in mouse brain was examined by immunohistochemistry. Two antibodies were used for these studies, ␣-SK2-C, directed toward the C terminus that recognizes both SK2 isoforms, and ␣-SK2-L, specific for the extended N terminus of SK2-L. These two antibodies produced almost identical patterns of immunoreactivity (see Sailer et al. (8) ). The notable exception was the lack of SK2-L staining in layer V of the cortex, where the pan SK2 antibody detected robust expression (Fig. 4, A and B) . Therefore, SK2-L and SK2-S are likely expressed in many of the same cells throughout the brain.
To examine the ability of SK2-L to form functional channels in a heterologous system, CHO cells were transfected with either SK2-S or SK2-L and examined for Ca 2ϩ -activated K Fig. 5A ). Additionally, cells were co-transfected with 4 g of SK2-L DNA plus 1 g of SK2-S DNA. The whole-cell current amplitudes were consistent with an additive, non-inhibitory effect (3.82 Ϯ 0.71 nA, n ϭ 6) suggesting the formation of either heteromeric channels or separate homomeric populations of SK2-L and SK2-S channels.
The Ca 2ϩ sensitivity of SK2-L channels was examined in inside-out patches. Although approximately equivalent wholecell current amplitudes were observed for SK2-S and SK2-L, in excised patches the current amplitudes for SK2-L were much smaller than for SK2-S. Ca 2ϩ dose responses were measured in symmetrical K ϩ solutions. Due to the small amplitudes of the Ca 2ϩ -dependent currents, the background current contributed significantly and slightly shifted the reversal potential. Therefore, the current recorded in 0 Ca 2ϩ was subtracted from the currents measured in Ca 2ϩ -containing solutions. The results showed that SK2-L channels have a Ca 2ϩ sensitivity similar to that of SK2-S (K D ϭ 0.64 Ϯ 0.09 M, Hill coefficient ϭ 1.35 Ϯ 0.03, n ϭ 3; Fig. 5B ). The Hill coefficient for SK2-L is less than for SK2-S (Ͼ4 (21)), but this likely reflects the difficulties presented by the very small currents.
The inconsistency between whole-cell and patch current amplitudes suggested that SK2-L might be non-uniformly distributed in the membrane, different from SK2-S (18). Therefore, COS cells expressing either form of SK2 harboring an external myc epitope tag (18) were examined for surface expression by ␣-myc immunohistochemical staining of live cells. The results showed that in contrast to the more uniform and diffuse distribution of SK2-S, SK2-L surface staining was strikingly punctate (Fig. 6) .
The heterologous co-expression results presented above did not distinguish between heteromeric or separate homomeric channel populations. To determine whether SK2-L co-assembles with the other SK subunits, ␣-SK2-L immunoprecipitations were performed. SK2-L was co-expressed in COS cells with SK1, SK2-S, or SK3, each harboring an N-terminal C8 epitope tag. Control experiments were performed by individually transfecting the C8-tagged SK1, SK2-S, and SK3 into COS cells. Prior to ␣-SK2-L immunoprecipitation, the lysates from these individually transfected cells were combined with an equal amount of lysate from cells transfected with only SK2-L. The Western blot presented in Fig. 7A shows equivalent expression levels of the C8-tagged channels in lysates from co-transfected (lanes 1-3) or individually transfected (lanes 4 -6) cells. A monoclonal antibody directed to the C8 tag was used to assess co-immunoprecipitation. SK1, SK2-S, and SK3 were co-immunoprecipitated with the ␣-SK2-L antibody only in the co-transfected cells and not in the control conditions (Fig. 7B) . Taken together, the results suggest that SK2-L subunits co-assemble into heteromeric channels with the other SK subunits.
To address whether SK2-L exists in heteromeric channels in brain, immunoprecipitations were performed with the ␣-SK2-L antibody. Brain extracts from SK2-null mice served as controls. The results showed that SK2-S and SK3, as well as calmodulin, co-immunoprecipitate with SK2-L from wild type brain membranes but not from membranes prepared from SK2-null mice (Fig. 8 ). SK2 appears to form aggregates under denaturing conditions; note the high molecular weight species in the eluate from wild type but not SK2⌬/⌬ mouse brains. Therefore, the intensity of the SK2-S monomer may represent an underestimate of the amount of SK2-S that co-precipitates with SK2-L. The interaction between SK2-L and SK1 in brain could not be assessed, as SK1-specific antisera capable of detecting SK1 in brain membrane preparations are not yet available. Immunoprecipitations from brain membranes using the pan ␣-SK2-C also showed co-immunoprecipitation of SK3 and CaM (data not shown).
DISCUSSION
The results show that the SK2 gene gives rise to two proteins that differ in the intracellular N-terminal domain. SK2-L maximally extends the open reading frame by 275 amino acids. It is not yet clear how the two proteins are generated from the SK2 gene. Two SK2 transcript species of ϳ2.5 kb are detected on Northern blots prepared from mouse brain RNA (6) . Even if the most 3Ј of the additional start codons is used (indicated in Fig.  2C ) for translational initiation of SK2-L, the SK2-L mRNA must be longer than the species so far detected by Northern blots. Probing Northern blots prepared with mouse brain total   FIG. 4 . Distribution of SK2-L and SK2-S in coronal sections of mouse hippocampus and neocortex. The pan-SK2 antibody ␣-SK2-C detected SK2 immunoreacivity throughout the CA1-CA3 region of the hippocampus and in cortical layer V neurons. A similar profile was observed for SK2-L immunoreactivity in hippocampus, while staining was not detected in cortex. Abbreviations: gl, granule cell layer; pl, polymorphic layer; ml, molecular layer; sl, stratum lucidum; so, stratum oriens; sp, stratum pyramidale; sr, stratum radiatum; V, neocortical layer V. Scale bar, 200 m.
or poly(A)
ϩ RNA with the exon C (see Fig. 2C ) sequence failed to detect specific transcripts; the same blots probed with exon 8 sequences that encode the distal portion of the SK2 protein, present in both SK2-S and SK2-L, detected only the ϳ2.5-kb bands. Therefore, SK2-L mRNA is expressed at significantly lower levels than SK2-S mRNA. It is also possible that SK2-L mRNA undergoes rapid turnover, reflected as low steady-state levels. Further analysis will determine the contributions of distinct SK2 promoters or alternative splicing to the genesis of the different mRNA forms.
The extended sequence unique to SK2-L contains an SH3-binding site as well as a potential MAP kinase substrate and several serine and threonine residues that may also serve as targets for phosphorylation. It also contains a motif with a core sequence of CXXC that has homology to regions in enzymes that transfer sulfur-containing moieties to metabolites, MoeZ and MoeB. The N-terminal extension of SK2-L described here is similar in length and shows some sequence homology with the N-terminal domain of SK3 ( Fig. 2C; Ref. 22) . Although SK2-L and SK3 share homology in this N-terminal region, an isoform of SK3 analogous to SK2-S is not detected in brain by an antibody directed to the C terminus of SK3 (8, 23 ). As shown above, an SK2 antibody directed to the intracellular C-terminal domain recognizes two SK2 species in mouse brain. Taken together the results suggest that the SK2 and SK3 genes give rise to analogous long forms of the proteins, but expression of a shorter form appears to be unique to SK2. In these studies, the comparison of immunoblots from wild type and SK2 null mice probed with a commercially available ␣-SK2 antibody revealed that this antibody recognizes three nonspecific bands in mouse brain extracts. In several other studies this antibody has been used to analyze the distribution and regulation of SK2 (24, 25) , and the conclusions may, therefore, have to be re-evaluated.
The distinct roles of the two SK2 isoforms in the central nervous system have yet to be determined. The distribution of immunoreactivity in brain slices using antibodies that detect either both forms or only SK2-L reveal only subtle differences in expression profile. Although limited by the inability to generate an antibody that specifically recognizes the short form of SK2, it appears that SK2-L is widely expressed in the brain. The relative abundance of SK2-L versus SK2-S is difficult to assess, although the results indicate qualitatively lower abundance for SK2-L.
SK2-L subunits co-assemble in brain with SK2-S and SK3 subunits. The lack of SK1-specific antibodies capable of detecting native SK1 protein in brain membrane preparations precludes an analysis of interaction between SK2-L and SK1 in vivo, but results from heterologous co-expression experiments suggest that native SK2-L and SK1 may also co-assemble. The migration of SK2-L under non-reducing denaturing conditions further suggests that SK2-L exists in a macromolecular complex held together by disulfide bonds. Alternatively, the altered migration may be due to disulfide bond formation that occurs during membrane preparation, which argues for the close proximity of other free cysteine residues on adjacent subunits or on tightly associated heterologous proteins. Indeed, the extended N-terminal domain of SK2-L contains two cysteine-rich islands. The cysteine residues in these regions may contribute to subunit-subunit interactions or mediate interactions with heterologous components of SK2 channel-containing complexes.
In heterologous expression studies, there was a trend suggesting that SK2-L whole-cell current amplitudes were smaller than those for SK2-S, although the differences did not reach significance. In contrast, SK2-L currents in excised patches were much smaller than those recorded for SK2-S. The small current amplitudes compromised the ability to obtain a detailed comparison of Ca 2ϩ sensitivity with SK2-S. However, there did not appear to be significant differences, as expected from the complete conservation of the core and intracellular domains of the two subunits. The low levels of patch currents were reflected by a marked difference in the surface distribution of SK2-L and SK2-S, as SK2-L was distributed to distinct puncta, while SK2-S had a diffuse surface distribution. The punctate distribution is likely due to functions endowed by the unique extended N-terminal domain that may cause aggregation and partitioning for homomeric SK2-L as well as affect trafficking. Immunoprecipitations from co-expressing COS cells and from brain show that SK2-L can co-assemble with other SK subunits. In this regard, the majority of SK2-L expressed in COS cells is, unlike native SK2-L, unaffected by oxidation/reduction conditions on SDS-PAGE which might reflect the absence or low abundance of a heterologous protein partner for SK2-L. It is possible that the extended N-terminal domain of SK2-L may direct subcellular distribution and incorporation of SK channels into heteromeric complexes.
